Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism

A feedback regulation of CREB activation through the CUL4A and ERK signaling

(2019) Cheemala Ashok et al.   MEDICAL ONCOLOGY

Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor–BTK Signaling Pathway

(2019) Qian Zhang et al.   JOURNAL OF IMMUNOLOGY

Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia

(2018) Md Kamrul Hasan et al.   BLOOD

WNT5A promotes migration and invasion of human osteosarcoma cells via SRC/ERK/MMP-14 pathway

(2018) Xingwen Wang et al.   CELL BIOLOGY INTERNATIONAL

Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia

(2018) Michael Y. Choi et al.   Cell Stem Cell

Dock2 in the development of inflammation and cancer

(2018) Yayun Chen et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma

(2018) Jian Yu et al.   Oncotarget

Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells

(2018) Md Kamrul Hasan et al.   LEUKEMIA

Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells

(2017) M K Hasan et al.   LEUKEMIA

Chronic lymphocytic leukaemia

(2017) Thomas J. Kipps et al.   Nature Reviews Disease Primers

Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL

(2016) A. Shukla et al.   BLOOD

High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia

(2016) B. Cui et al.   BLOOD

CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes

(2016) Soizic Garaud et al.   Cellular & Molecular Immunology

Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia

(2016) Elisa ten Hacken et al.   JOURNAL OF IMMUNOLOGY

SOS1, ARHGEF1, and DOCK2 rho-GEFs Mediate JAK-Dependent LFA-1 Activation by Chemokines

(2016) Lara Toffali et al.   JOURNAL OF IMMUNOLOGY

Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib

(2016) J Yu et al.   LEUKEMIA

Unravelling the Mechanism of TrkA-Induced Cell Death by Macropinocytosis in Medulloblastoma Daoy Cells

(2016) Chunhui Li et al.   MOLECULAR AND CELLULAR BIOLOGY

Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1

(2015) Michael Y. Choi et al.   Clinical Lymphoma Myeloma & Leukemia

Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation

(2015) Jian Yu et al.   JOURNAL OF CLINICAL INVESTIGATION

BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia

(2015) S-S Chen et al.   LEUKEMIA

The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine

(2015) Kyle Crassini et al.   LEUKEMIA & LYMPHOMA

BRAF inhibitor–associated ERK activation drives development of chronic lymphocytic leukemia

(2014) Niuscha Yaktapour et al.   JOURNAL OF CLINICAL INVESTIGATION

A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics

(2014) Apirat Chaikuad et al.   Nature Chemical Biology

The Pathogenesis of Chronic Lymphocytic Leukemia

(2013) Suping Zhang et al.   Annual Review of Pathology-Mechanisms of Disease

Targeting B-cell anergy in chronic lymphocytic leukemia

(2013) B. Apollonio et al.   BLOOD

BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity

(2013) S Cheng et al.   LEUKEMIA

ROR1 can interact with TCL1 and enhance leukemogenesis in E -TCL1 transgenic mice

(2013) G. F. Widhopf et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors

(2013) E. J. Morris et al.   Cancer Discovery

The Onco-Embryonic Antigen ROR1 Is Expressed by a Variety of Human Cancers

(2012) Suping Zhang et al.   AMERICAN JOURNAL OF PATHOLOGY

Blockade of Inflammatory Responses by a Small-Molecule Inhibitor of the Rac Activator DOCK2

(2012) Akihiko Nishikimi et al.   CHEMISTRY & BIOLOGY

ERK1/2 MAP kinases: Structure, function, and regulation

(2012) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Elucidating the CXCL12/CXCR4 Signaling Network in Chronic Lymphocytic Leukemia through Phosphoproteomics Analysis

(2010) Morgan O'Hayre et al.   PLoS One

Sequential Regulation of DOCK2 Dynamics by Two Phospholipids During Neutrophil Chemotaxis

(2009) A. Nishikimi et al.   SCIENCE

ERK signaling regulates tumor promoter induced c-Jun recruitment at the Fra-1 promoter

(2008) Pavan Adiseshaiah et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia

(2008) S. Baskar et al.   CLINICAL CANCER RESEARCH

Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy

(2008) Amir H. DaneshManesh et al.   INTERNATIONAL JOURNAL OF CANCER

Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a

(2008) T. Fukuda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA